Is Concert Pharmaceuticals’ approach to drug development an artful way around patent law, or a safer route to build a drug? Maybe both.
The Massachusetts company is developing close facsimiles to the cystic fibrosis drug Kalydeco and the cancer drug Jakafi. They’re not quite biosimilars, nor are they generics — they’re therapies that are just different enough structurally from the established drugs to be considered unique pharmaceuticals.
About the Author Reprints
